Skip to main content

DXCM

Stock

DXCM

Stock
Health Care
Medical Devices

Performance overview

DXCM Price
Price Chart

Forward-looking statistics

Beta
1.02
Risk
49.09%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Company info

SectorHealth Care
IndustryMedical Devices
Employees7K
Market cap$46.0B

Fundamentals

Enterprise value$34.1B
Revenue$4.1B
Revenue per employee—
Profit margin12.90%
Debt to equity113.97

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1.33
Dividend per share—
Revenue per share$10.53
Avg trading volume (30 day)$281M
Avg trading volume (10 day)$381M
Put-call ratio—

Macro factor sensitivity

Growth-0.8
Credit+3.6
Liquidity+1.5
Inflation-3.0
Commodities-0.3
Interest Rates-2.4

Valuation

Dividend yield0.00%
PEG Ratio40.85
Price to sales7.84
P/E Ratio40.85
Enterprise Value to Revenue8.22
Price to book14.35

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend day—

News

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Zacks Investment Research (July 3, 2025)
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.

CNBC (April 30, 2025)
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch

The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.

Benzinga (April 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free